- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-18-0048657

About Vanquest Pharma Private Limited
Data last updated:
Vanquest Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 June 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24304MH2019PTC326607. Its GSTIN is 27AAGCV9740D1Z4 (Maharashtra).
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹1 Cr. It is led by directors including Pavan H Patel and Hiten Patel.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹39.34 Cr, a decline of 15% compared to the previous year. For the same year it recorded a net loss of ₹29.48 Cr (net margin -74.9%) and EBITDA of -₹11.17 Cr (EBITDA margin -28.4%). Revenue has grown at a compounded annual rate (CAGR) of 542% over three years.
The company has about 48 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Vanquest Pharma. As per MCA filings, the company has open charges of ₹60 Cr and satisfied charges of ₹53.2 Cr on record. The company has 2 deals on record (1 rights issue, 1 secondary share transfer); the latest was in May 2022. Its 10 peer companies in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Shruti Drugs Private Limited with revenue of ₹39.47 Cr.
Vanquest Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0048657). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vanquestpharma.com.
Company details
Recognitions & Rankings of Vanquest Pharma
Contact details
Vanquest Pharma Private Limited's registered office is in Mumbai, Maharashtra. Its website is vanquestpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address208 Town Centre Comm Prem Coop Soc Ltd, Nr Mahalaxmi Andheri East, Mumbai, Maharashtra, India – 400059
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Vanquest Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Vanquest Pharma operates one associated brand: Vanquest Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| API manufacturing and regulatory services in the healthcare sector. | vanquestpharma.com |
Business activity
The main business activity of Vanquest Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Vanquest Pharma Private Limited, buy the company report.
Financials of Vanquest Pharma Private Limited
FY 2025 filings availableVanquest Pharma Private Limited reported revenue of ₹39.34 Cr (down 15% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 15% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 542%. EBITDA fell 11% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹11.17 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹29.48 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -28.4% | ||||
| Net Profit Margin | -74.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Vanquest Pharma Private Limited, buy the company report.
Board of directors of Vanquest Pharma Private Limited
Vanquest Pharma has 6 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pavan H Patel | Director | 12 Jun 2019 | 7 Years 5 Months | Current |
| Hiten Patel | Director | 12 Jun 2019 | 7 Years 5 Months | Current |
| Manish Babulal Jain Also directs: Medorbis Trade LLP, Naprod Life Sciences Private Limited, Miracalus Pharma Private Limited and 2 more | Director | 12 Jun 2019 | 7 Years 5 Months | Current |
| Mohan Babulal Jain Also directs: Medorbis Trade LLP, Naprod Life Sciences Private Limited, Miracalus Pharma Private Limited and 2 more | Director | 12 Jun 2019 | 7 Years 5 Months | Current |
| Pratik Hitenkumar Patel | Director | 12 Jun 2019 | 7 Years 5 Months | Current |
| Aarya Mohan Jain Also directs: Medorbis Trade LLP, Naprod Life Sciences Private Limited, Miracalus Pharma Private Limited and 1 more | Additional Director | 26 Mar 2025 | 1 Years 7 Months | Current |
Peer comparison
Vanquest Pharma Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Shruti Drugs Private Limited | ₹39.47 Cr (FY 2025) | 35.0% | Secunderabad, Telangana, India | |||
| Acechemie Zynk Energy Limited | ₹39.46 Cr (FY 2024) | 3.0% | Amod, Gujarat, India | |||
| QB Biotechnology Private Limited | ₹39.42 Cr (FY 2025) | 47.0% | Mumbai, Maharashtra, India | |||
| Eurosyntec Chemicals Private Limited | ₹39.41 Cr (FY 2025) | 6.0% | Navi Mumbai, Maharashtra, India | |||
| Rex Remedies Limited | ₹39.37 Cr (FY 2025) | -11.0% | Delhi, India | |||
| Vanquest Pharma Private Limitedthis company | ₹39.34 Cr (FY 2025) | -₹29.48 Cr | -74.9% | -15.0% | 48 | Mumbai, Maharashtra, India |
| Carbon Light Private Limited | ₹39.32 Cr (FY 2025) | 120.0% | Ghaziabad, Uttar Pradesh, India | |||
| Strides Emerging Markets Limited | ₹39.32 Cr (FY 2020) | 735.0% | Bangalore, Karnataka, India | |||
| Giyaan Pharma Private Limited | ₹39.31 Cr (FY 2024) | 16.0% | Hyderabad, Telangana, India | |||
| Qipc Eae India Private Limited | ₹39.29 Cr (FY 2024) | 46.0% | Sanand, Gujarat, India | |||
| Discovery Laboratories Private Limited | ₹39.29 Cr (FY 2025) | 99.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Vanquest Pharma Private Limited, buy the company report.
Auditor
Vanquest Pharma Private Limited is audited by SohanS.Jain& Co. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SohanS.Jain& Co. | FY 2024 | 110327W |
Shareholding
The shareholding of Vanquest Pharma Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Vanquest Pharma Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Mar 2024 | 100889207 | Others | ₹60 Cr | Open | |
| 27 Aug 2021 | 100479800 | Others | ₹53.2 Cr | Satisfied |
To see the full charge records of Vanquest Pharma Private Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Vanquest Pharma Private Limited has 2 deals on record (1 rights issue, 1 secondary share transfer); the latest was in May 2022.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2022 | Rights issue | ₹99 Lakh | Investors: 4 individuals |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Vanquest Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Vanquest Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Vanquest Pharma Private Limited has a workforce of 48 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 48 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 |
To see the full employee and EPFO history of Vanquest Pharma Private Limited, buy the company report.
GST
Vanquest Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAGCV9740D1Z4 | Maharashtra | Active | 24 Jul 2019 |
To see the full GST registrations and return filing status of Vanquest Pharma Private Limited, buy the company report.
Recent activity
Vanquest Pharma Private Limited has 8 board changes on record since 2019: 6 appointments and 2 cessations. The latest: Aarya Mohan Jain was appointed as Additional Director on 26 Mar 2025.
4 earlier events are in the company report.
Frequently asked questions
Vanquest Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 June 2019 (7+ years old) and is registered under CIN U24304MH2019PTC326607.
Vanquest Pharma has 6 current directors:
- Pavan H Patel - Director
- Hiten Patel - Director
- Manish Babulal Jain - Director
- Mohan Babulal Jain - Director
- Pratik Hitenkumar Patel - Director
- Aarya Mohan Jain - Additional Director
The latest financial statements of Vanquest Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 26 September 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Vanquest Pharma is 27AAGCV9740D1Z4, registered in Maharashtra.
The CIN (Corporate Identification Number) of Vanquest Pharma is U24304MH2019PTC326607. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Vanquest Pharma was incorporated on 12 June 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.
Vanquest Pharma has 2 deals on record (1 rights issue, 1 secondary share transfer); the latest was in May 2022.
The peers of Vanquest Pharma by revenue are Shruti Drugs Private Limited, Acechemie Zynk Energy Limited, QB Biotechnology Private Limited, Eurosyntec Chemicals Private Limited, Rex Remedies Limited and 5 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Aarya Mohan Jain was appointed as Additional Director on 26 Mar 2025. Kamala Babulal Jain ceased to be Director on 25 Mar 2025. Babulal Kesharimal Jain ceased to be Director on 08 Jan 2021. Vanquest Pharma has 8 board changes on record in total.
Yes, Vanquest Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-18-0048657).
Vanquest Pharma can be reached through the website vanquestpharma.com. Its registered office is in Mumbai, Maharashtra, India.

